These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 23248249)
1. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249 [TBL] [Abstract][Full Text] [Related]
2. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852 [TBL] [Abstract][Full Text] [Related]
3. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. Pautas C; Merabet F; Thomas X; Raffoux E; Gardin C; Corm S; Bourhis JH; Reman O; Turlure P; Contentin N; de Revel T; Rousselot P; Preudhomme C; Bordessoule D; Fenaux P; Terré C; Michallet M; Dombret H; Chevret S; Castaigne S J Clin Oncol; 2010 Feb; 28(5):808-14. PubMed ID: 20048183 [TBL] [Abstract][Full Text] [Related]
4. [Improved treatment results in children with AML: Results of study AML-BFM 93]. Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M; Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551 [TBL] [Abstract][Full Text] [Related]
5. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311 [TBL] [Abstract][Full Text] [Related]
6. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777 [TBL] [Abstract][Full Text] [Related]
7. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group]. Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474 [TBL] [Abstract][Full Text] [Related]
9. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R; Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985 [TBL] [Abstract][Full Text] [Related]
10. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424 [TBL] [Abstract][Full Text] [Related]
11. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631 [TBL] [Abstract][Full Text] [Related]
12. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Latagliata R; Breccia M; Fazi P; Iacobelli S; Martinelli G; Di Raimondo F; Sborgia M; Fabbiano F; Pirrotta MT; Zaccaria A; Amadori S; Caramatti C; Falzetti F; Candoni A; Mattei D; Morselli M; Alimena G; Vignetti M; Baccarani M; Mandelli F Br J Haematol; 2008 Dec; 143(5):681-9. PubMed ID: 18950458 [TBL] [Abstract][Full Text] [Related]
13. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results]. Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773 [TBL] [Abstract][Full Text] [Related]
14. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. Adige S; Lapidus RG; Carter-Cooper BA; Duffy A; Patzke C; Law JY; Baer MR; Ambulos NP; Zou Y; Bentzen SM; Emadi A Cancer Chemother Pharmacol; 2019 Jun; 83(6):1105-1112. PubMed ID: 30968179 [TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients. Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651 [TBL] [Abstract][Full Text] [Related]
16. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia]. Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684 [TBL] [Abstract][Full Text] [Related]
17. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. Büchner T; Berdel WE; Haferlach C; Haferlach T; Schnittger S; Müller-Tidow C; Braess J; Spiekermann K; Kienast J; Staib P; Grüneisen A; Kern W; Reichle A; Maschmeyer G; Aul C; Lengfelder E; Sauerland MC; Heinecke A; Wörmann B; Hiddemann W J Clin Oncol; 2009 Jan; 27(1):61-9. PubMed ID: 19047294 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823 [TBL] [Abstract][Full Text] [Related]
19. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A; J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036 [TBL] [Abstract][Full Text] [Related]
20. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. Büchner T; Schlenk RF; Schaich M; Döhner K; Krahl R; Krauter J; Heil G; Krug U; Sauerland MC; Heinecke A; Späth D; Kramer M; Scholl S; Berdel WE; Hiddemann W; Hoelzer D; Hehlmann R; Hasford J; Hoffmann VS; Döhner H; Ehninger G; Ganser A; Niederwieser DW; Pfirrmann M J Clin Oncol; 2012 Oct; 30(29):3604-10. PubMed ID: 22965967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]